RESEARCH Open Access



CircRNA has_circ_0017109 promotes lung tumor progression via activation of Wnt/β-catenin signaling due to modulating miR-671-5p/FZD4 axis

Bo Yang^{1,2,3†}, Bin Zhang^{1,2,3†}, Qi Qi^{1,2,3†} and Changli Wang^{1,2,3*}

Abstract

Introduction: Accumulating evidence highlights the critical roles of circular RNAs (circRNAs) in the malignant progression of cancers. In this study, we investigated the expression pattern of a newly identified circRNA (hsa_circ_0017109) in non–small cell lung cancer (NSCLC), and examined its downstream molecular targets.

Methods: Quantitative real-time PCR (qRT-PCR) and Western blotting (WB) were conducted to quantify gene and protein expression. In vitro functional assays such as colony formation assay, cell counting kit-8 (CCK-8) and flow cytometry were used to study cell proliferation and apoptosis. RNA pull-down assay, luciferase reporter assay and RNA immunoprecipitation were performed to validate molecular interaction. Mouse xenograft model of NSCLC cells was used to assess the role of circ_0017109 in tumorigenesis.

Results: Circ_0017109 was upregulated in NSCLC tumor samples and cells. Silencing circ_0017109 impaired cell proliferation and promoted apoptosis in NSCLC cells, and circ_0017109 knockdown suppressed in vivo tumorigenesis of NSCLC cells in mouse xenograft model. MiR-671-5p was identified as a target of circ_0017109, and circ_0017109 negatively impacted on miR-671-5p expression. MiR-671-5p downregulated FZD4 and dampened the activity of Wnt/β-catenin signaling pathway. Circ_0017109 modulated FZD4 expression by suppressing miR-671-5p activity.

Conclusions: Elevated circ_0017109 expression promotes tumor progression of NSCLC by modulating miR-671-5p/FZD4/β-catenin axis.

Keywords: circRNA, NSCLC, Lung cancer, miRNA, FZD4, Wnt/β-catenin

Introduction

Non-small cell lung cancer (NSCLC) is a dominant subtype of lung cancers, accounting for approximately 85% of total diagnoses in lung cancer [1]. Unfortunately, the diagnosis of NSCLC is often made in the late stage due to insidious and asymptomatic nature of the disease [1]. Due to the poor prognosis of patients with advanced NSCLC, the 5 years's survival rate of NSCLC patients is dismay despite the advances in treatment strategies [2]. To achieve satisfactory treatment outcome, early diagnosis is critical for optimal surgery and the choice of effective adjuvant therapy. Identification of diagnostic and prognostic biomarkers for NSCLC is imperative for the early diagnosis and the selection of effective treatment scheme. The wide application of next-generation sequencing

³ Tianjin's Clinical Research Center for Cancer, Tianjin Lung Cancer Center, Huan-hu-xi Road, Ti-Yuan-Bei, He XI Disrict, Tianjin 30060, P.R. China Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

 $^{^{\}dagger}$ Bo Yang, Bin Zhang and Qi Qi contributed equally to this work.

^{*}Correspondence: biuk124@163.com

technologies enables the characterization of gene regulatory networks in cancer. Circular ribonucleic acid (circRNAs) emerges as a novel family of non-coding RNAs which are recognized as potential diagnostic biomarkers for certain cancers [3].

CircRNAs are previously considered as aberrant byproducts of messenger RNA splicing; however, recent studies clarified that they play pivotal regulatory roles in multiple cellular processes [3]. These functional molecules exist as closed-loop structure resulted from the back-splicing, and hence show high stability. CircRNAs are broadly expressed in mammalian cells with tissue-specific and cell-specific pattern. Recent efforts unveiled different mechanisms of action of circRNAs: they may act as microRNA (miRNA) sponges or decoys; they may bind to certain target protein to modulate their activity; or occasionally they are translated into small peptides [4]. The best-characterized biological activity of circRNAs is the molecular sponge of miRNA. Each circRNA can harbor multiple miRNA binding sites and the physical absorption of miRNAs affects the activity and stability of miRNAs. Dysregulation of circRNAs has been implicated in the development of gastric cancer (GC) [5, 6], colorectal cancer (CRC) [7, 8], ovarian [9], bladder [10], and breast cancer (BC) [11]. It has been also noticed that the same circRNA may display different mode of actions in different types of cancers.

Has_circ_0017109 is one of the most recently identified circRNAs, which may play a critical function in lung cancer occurrence and development. Initially, our analyses on the microarray dataset profiling noncoding RNAs in NSCLC tissues and adjacent normal tissues (GSE101586 and GSE112214) revealed that, circ_0017109 expression was significantly higher in NSCLC tumors samples in comparison to the matched normal samples. The functional role of circ 0017109, however, has not yet been studied in NSCLC. Previous studies identified miR-671-5p as the miRNA target of circ_0017109, and miR-671-5p expression was suppressed within several malignant tumors, like osteosarcoma [12], BC [13, 14], and glioblastoma (GBM) [15]. Interestingly, frizzled-4 (FZD4, the upstream regulator of Wnt/ β -catenin) was downregulated in the above process, along with the suppression of Wnt/βcatenin signaling [16, 17]. In this study, we first investigated the functional role of circ_0017109 in regulating the malignant phenotype and tumorigenesis of NSCLC cells. We further validated the functional interaction of circ_0017109 and miR-671-5p, and demonstrated that miR-671-5p/FZD4 axis mediated the functional role of circ_0017109.

Results

Circ_0017109 is upregulated in NSCLC and associated with the prognosis of NSCLC patient

Through analyzing GSE101586 and GSE112214 microarray data of non-coding RNA profiling in NSCLC tumor and normal tissues, we found that circ_0017109 showed higher expression in NSCLC samples when compared to normal tissue (Fig. 1A). We then collected 50 pairs of NSCLC samples and the matched non-carcinoma samples, and qRT-PCR assay confirmed the upregulation of circ_0017109 in NSCLC (Fig. 1B). Accordingly, circ 0017109 level was elevated in NSCLC cells (A549, CALU3, H1229, CALU6) when compared to human bronchial epithelial cells (HBE, Fig. 1C). To confirm the circularity of circ_0017109, RNA samples extracted from A549 and H1229 cells were treated with RNase R. Compared to the linear mRNA of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) which was degraded by RNase R, circ_0017109 was highly resistant to RNase R digestion (Fig. 1D). According to the quantification of the nuclear and cytoplasmic fractions, circ_0017109 showed a predominant localization in the cytoplasmic fraction in A549 and H1229 cells (Fig. 1E).

Additionally, we analyzed the clinicopathological features of 50 patients with NSCLC and examined the association with circ_0017109 expression level. The median expression value of circ_0017109 was used as the cutoff to assign the patients into low- and high-expression groups (Table 1). We found a significant association between high expression of circ_0017109 and tumor size, lymph node metastasis (LNM) and TNM stages (p < 0.05). Next, Kaplan-Meier (K-M) plot was adopted to analyze the prognostic value of circ_0017109 level in patients with NSCLC. High level of circ_0017109 expression was associated with an worse overall survival among NSCLC cases (p < 0.01; Fig. 1F). Taken together, circ_0017109 was upregulated within NSCLC, which showed positive correlations with malignant features of NSCLC. These results highlight the potential applicability of circ_0017109 as a prognostic biomarker in NSCLC.

Circ_0017109 is essential to support the proliferation and survival of NSCLC cells

To study the function of circ_0017109 in NSCLC cells, we applied siRNA targeting circ_0017109 in A549 and H1299 cells. After transfection, circ_0017109 level was significantly reduced in both cell lines (Fig. 2A). CCK-8 assay showed that silencing circ_0017109 suppressed cell growth in comparison to the control group (Fig. 2B). Consistently, colony forming experiment suggested the transfection with si_circ_0017109 significantly




Fig. 1 Circ_0017109 is upregulated in NSCLC and associated with poor prognosis in NSCLC patients. **A** Expression of circ_0017109 in normal lung tissues and NSCLC tumor samples of GSE101586 and GSE112214 (GEO). **B** Circ_0017109 levels within 50 pairs of NSCLC samples and matched non-carcinoma samples. **C** Circ_0017109 levels within NSCLC cells, (A549, CALU3, H1229 and CALU6) and human normal bronchial epithelial cells (HBE). **D** GAPDH and circ_0017109 levels in the RNA samples from H1229 and A549 cell lines with or without RNase R treatment. **E** RNA levels of circ_0017109, U6 (nuclear control), and GAPDH (cytoplasmic control) in the cytoplasmic and nuclear fraction of H1229 and A549 cells. **F** The association of NSCLC patient overall survival and circ_0017109 expression level. *, P < 0.05, and ***, P < 0.001

 Table 1
 Correlation between clinicopathological characteristics of NSCLC patients and circ_0017109 expression level

Clinicopathological features		No.	Low circ_0017109 expression (<i>n</i> = 25)	High circ_0017109 expression (<i>n</i> = 25)	<i>P</i> -value
Age	≥65	26	12	14	0.5713
	<65	24	13	11	
Gender	Male	22	10	12	0.5688
	Female	28	15	13	
Tumor size	≥3 cm	23	8	15	0.047
	<3 cm	27	17	10	
Differentiation	Well-Moderate	32	19	13	0.0771
	Poor	18	6	12	
Lymph node metastasis	Positive	15	4	11	0.0308
	Negative	35	21	14	
TNM stage	1+11	28	18	10	0.0227
	III + IV	22	7	15	




Fig. 2 Circ_0017109 promotes cell growth and inhibits apoptosis of NSCLC cells. **A** Circ_0017109 expression within H1299 and A549 cells after the transfection of si-circ_0017109 or si-NC. **B** CCK-8 assay in H1299 and A549 cells after the transfection of si-circ_0017109 or si-NC. **C** Colony formation assay in H1299 and A549 cells after the transfection of si-circ_0017109 or si-NC. **D** Apoptosis detection in H1299 and A549 cells after the transfection of si-circ_0017109 or si-NC. **E** Protein levels of cleaved-caspase-3 and Bcl-2 in H1299 and A549 cells after the transfection of si-circ_0017109 or si-NC. **, \$P < 0.01\$, and ****, \$P < 0.001\$

reduced colony forming capacity in both cells (Fig. 2C). In circ_0017109-silenced cells, we observed an increased proportion of apoptotic cells in relative to cells transfected with si-NC (Fig. 2D). We also evaluated the apoptosis-related proteins such as B-cell lymphoma-2 (Bcl-2) and cleaved-caspase-3. Circ-0017109 knockdown promoted the cleavage of caspase-3 (proapoptotic) while Bcl-2 (anti-apoptotic) level was downregulated (Fig. 2E). To strengthen our finding, we also applied a second siRNA to knock down circ 0017109 in A549 and H1299 cells. The results further validated that downregulating circ 0017109 undermines cell proliferation and induced apoptosis in NSCLC cells (Fig. S1A-C). Altogether, these findings suggest an indispensable role of circ_0017109 in sustaining cell proliferation and survival in NSCLC cells.

miR-671-5p is directly regulated by circ_0017109

To find the potential targets of circ_0017109, we searched the CircInteractome database (https://circinteractome.nia.nih.gov/) and identified multiple

potential miRNA targets of circ_0017109 (Fig. S2A). To narrow down the targets of circ_0017109, we performed qRT-PCR analysis of these miRNAs between NSCLC cells and human bronchial epithelial HBE cells. The results revealed that only miR-671-5p showed downregulation in A549 and H1299 cells, when compared to HBE cells (Fig. S2B). Since circ_0017109 was upregulated in A549 and H1299 cells, these data indicate a potential sponging effect of circ_0017109 on miR-671-5p. We therefore selected miR-671-5p as the candidate target of circ_0017109 for the following study.

We cloned the wild type binding sites in circ_0017109 (WT) or mutated binding sequences (MUT) into a luciferase reporter to study their potential functional interaction (Fig. 3A). In H293T cells, the transfection of miR-671-5p mimic suppressed luciferase activity of WT reporter, while in MUT reporter miR-671-5p mimic showed no suppression (Fig. 3A). The data suggest that circ_0017109 and miR-671-5p interact through the predicted binding sequence. We further conducted RNA pull-down assay to verify their physical association, in




Fig. 3 MiR-671-5p is regulated by circ_0017109. **A** Predicted miR-671-5p target sequences in circ_0017109 sequence based on CircInteractome database. Luciferase activity of wide-type or mutated circ_0017109 reporter was determined in H293K cells in the presence of miR-NC or miR-671-5p mimic. **B** RNA-pull down assay of circ_0017109 enrichment using biotinylated miR-671-5p or biotin-NC. **C** RNA-immunoprecipitation assay using anti-AGO2 antibody or nonspecific rabbit IgG. ****, *P* < 0.001

which biotinylated NC probe (biotin-NC) and miR-671-5p (biotin-miR-671-5p) were transfected into A549 and H1229 cells. In both cell lines, circ_0017109 showed significant enrichment by biotin-miR-671-5p when compared to biotin-NC probe (Fig. 3B). Using an antibody against argonaute 2 (AGO2), we then performed RNA immunoprecipitation assay (RIP) in A549 and H1299 cells, with IgG isotype as the control. We observed that both miR-671-5p and circ_0017109 were significantly enriched by anti-AGO2 antibody (Fig. 3C). Collectively, these results provided further evidence for the physical binding and association between circ_0017109 with miR-671-5p in NSCLC cells.

Circ_0017109 promotes FZD4 expression via sponging miR-671-5p

To search for the mRNA target of miR-671-5p, we used different online databases to predict the potential interacting mRNA of miR-671-5p. Through prediction, it is found that miR-671-5p could target FZD3, FZD4 and FZD7 in TargetMiner database (https:// www.isical.ac.in/~bioinfo_miu/targetminer20.htm); miR-671-5p could potentially bind to FZD2 and FZD3 mRNA in Targetscan database (http://www.targetscan. org/vert_71/). We then performed qRT-PCR analysis of FZD2, FZD3, FZD4 and FZD7 mRNA in NSCLC cells and human bronchial epithelial HBE cells. The results showed that compared to control (HBE cells), FZD4 showed the highest expression in A549 and H1299 cells (Fig. S3). Since circ_0017109 upregulation in A549 and H1299 cells could sponge miR-671-5p, we therefore hypothesized that circ_0017109/ miR-671-5p axis regulates FZD4 expression. To investigate this hypothesis, we performed dual luciferase reporter assay using WT or MUT reporter of FZD4 binding sites as illustrated by Fig. 4A. The co-transfection of miR-671-5p mimic significantly decreased the luciferase activity of FZD4 WT reporter, but such inhibition was not detected using FZD4 MUT reporter (Fig. 4B). Accordingly, both mRNA and protein levels of FZD4 in H1229 and A549 cells showed downregulation upon the transfection of miR-671-5p mimic (Fig. 4C). Besides, circ_0017109 knockdown reduced the protein level of FZD4, while the co-transfection of miR-671-5p inhibitor partially rescued FZD4 level (Fig. 4D). To show their expression pattern in NSCLC tumors and normal tissues, we performed qRT-PCR to detect the expression of FZD4 and miR-671-5p. It was found that FZD4 level was increased while miR-671-5p level was reduced in NSCLC tumor samples (Fig. 4E and F). Additionally, relative FZD4 level was positively related to circ_0017109 level but negatively related to miR-671-5p expression (Fig. 4G and H).

Altogether, these data suggest that the sponging activity of circ_0017109 on miR-671-5p consolidates FZD4 expression.

Circ_0017109 promotes the proliferation and survival of NSCLC cells through modulating miR-671-5p/FZD4 axis

To show the role of FZD4 as a downstream effector of circ 0017109, pcDNA3.1-FZD4 expression vector was transfected into H1229 and A549 cells. Compared to the empty vector (control), FZD4 vector significantly increased FZD4 mRNA and protein levels (Fig. 5A). Knockdown of circ_0017109 significantly reduced A549 and H1299 cell growth, and both miR-671-5p inhibitor and FZD4 overexpression restored cell growth capacity (Fig. 5B). We also observed a 70% reduction in clonogenic ability of A549 and H1299 cells after circ_0017109 knockdown, and both miR-671-5p inhibitor and FZD4 overexpression rescued the colony formation capacity (Fig. 5C). Consistently, apoptosis induction by circ 0017109 knockdown in A549 and H1229 cells were suppressed by miR-671-5p inhibitor and FZD overexpression (Fig. 5D), which was further evidenced by the changes in cleaved caspase-3 and Bcl-2 protein levels (Fig. 5E). As FZD is an upstream regulator of WNT/β-catenin signaling, we also examined the protein changes in this pathway. It was found that circ_0017109 silencing reduced the level of β -catenin, non-phospho (active) β -catenin, as well as the positive regulators of cell cycles including cyclin D1 and c-Myc. (Fig. 5F). The co-transfection of miR-671-5p inhibitor or FZD overexpression increased the expression levels of these proteins. Together, these finding imply that circ_0017109/ miR-671-5p axis modulates WNT/βcatenin signaling by targeting FZD4.

Circ_0017109 promotes oncogenesis of NSCLC cells in mouse model

The xenograft mouse model of NSCLC cells were established in nude mice using A549 cells stably expressing sh-NC (scramble shRNA) or shRNA targeting circ_0017109. We found that A549 cells with stable silencing of circ_0017109 showed retarded tumor growth ability and resulted in less tumor tissues in nude mice (Fig. 6A and B). We also performed WB using xenograft tumor tissues to analyze WNT/FZD4/β-catenin singling process. We found that in tumor tissues with circ_0017109 knockdown, FZD4, β-catenin and nonphospho β-catenin, cyclin D1, and c-Myc showed significant reduction, and a higher level of cleaved caspase-3 and a lower level of Bcl-2 were also detected (Fig. 6C). These findings were consistent with in vitro cell experiments, indicating that downregulation of circ_0017109 inhibits the tumorigenesis of A549 cells by targeting FZD4 and WNT/ β -catenin signaling.

Yang et al. BMC Pulmonary Medicine (2022) 22:443




Fig. 4 Circ_0017109 promotes FZD4 expression via sponging miR-671-5p. **A** miR-671-5p target sequence in the FZD4 3'-UTR was predicted using Targetscan database. **B** Luciferase activity of wild type or mutated FZD4 reporter in the presence of miR-NC or miR-671-5p mimic. **C** FZD4 mRNA and protein expression in H1229 and A549 cells after the transfection of miR-671-5p mimic. **D** The effect of circ_0017109 silencing and miR-671-5p inhibitor on FZD4 protein level. **E** Relative FZD4 expression in NSCLC tumor and normal lung tissue samples. **F** Relative miR-671-5p levels in NSCLC tumor and normal lung tissue samples. **G** Correlation of FZD4 expression and miR-671-5p in NSCLC tumor samples. **H** FZD4 level and circ_0017109 expression in NSCLC tumor samples. ****, *P*<0.001 compared with si-NC group, and ^^^, *P*<0.001 compared with si-circ_0017109 group


Discussion

The relevance of circRNAs in human cancer has drawn intensified research attention, and over 100,000 unique human circRNAs have been annotated [18, 19]. However, their functional characterization is far from completion

in the context of cancer. The expression pattern and regulatory network of circRNAs in human cancer remain largely unexplored. The present study focused on the delineation of the functional role and regulatory mechanism of circ_0017109 in NSCLC. Circ_0017109 showed

(See figure on next page.)

Fig. 5 Circ_0017109 modulates miR-671-5p/FZD4 axis and Wnt/β-catenin pathway. **A** FZD4 overexpression in H1229 and A549 cells upon the transfection of FZD4 expression vector. **B** CCK-8 assay in A549 and H1299 cells transfected with si-circ_0017109, si-NC, si-circ_0017109 + miR-671-5p inhibitor, or si-circ_017109 + FZD4. **C** Colony forming assays in A549 and H1299 cells transfected with si-circ_0017109, si-NC, si-circ_017109 + miR-671-5p inhibitor, or si-circ_0017109 + FZD4. **D** Apoptosis in A549 and H1299 cells transfected with si-circ_0017109, si-NC, si-circ_017109 + miR-671-5p inhibitor, or si-circ_017109 + FZD4. **E** Cleaved-caspase-3 and Bcl-2 levels within H1229 and A549 cells post-transfection. **F** Protein levels of FZD4, Bcl-2, β-catenin, non-phospho β-catenin, c-myc, cyclin D1, and cleaved caspase-3 in A549 and H1299 cells transfected with si-circ_0017109, si-NC, si-circ_0017109 + miR-671-5p inhibitor, or si-circ_0017109 + FZD4. **, P < 0.01, ***, P < 0.001 compared with si-NC group, $^{\wedge}$, $^{\wedge}$ 0.05, and $^{\wedge\wedge\wedge}$, $^{\wedge}$ 0.001 compared with si-circ_0017109 group






Fig. 6 Xenograft tumorigenesis assay in nude mice. **A** Subcutaneous xenograft volumes and **B** weights were measured in mice injected with A549 cells stably expressing sh-NC and shRNA targeting circ_0017109. **C** Protein levels of cleaved caspase-3, FZD4, β-catenin, non-phospho β-catenin, Bcl-2, c-myc and cyclin D1 in xenograft tumor tissues with sh-NC or shRNA targeting circ_0017109. ***, P < 0.001

an overexpression within NSCLC cells and tissues, and there was a correlation between its high expression and poor overall survival in NSCLC cases. Notably, based on our in vivo and in vitro results, circ_0017109 was required to sustain the proliferation and survival of NSCLC cells by sponging miR-671-5p and maintaining the activity of FZD4/Wnt/ β -catenin pathway.

A growing body of circRNAs were found to be aberrantly expressed in NSCLC, and they function as either oncogenes [20-26] or tumor suppressors [27-29]. For instance, amplification or overexpression of circRNAs, including circRNA_102231 [23], circPVT1 [20], ciRS-7/ CDR1as [24], circRNA 100,146 [26], and circFGFR1 [25], can downregulate tumor suppressors or negative regulators in cell division, thereby contributing to uncontrolled proliferation and tumorigenesis in NSCLC. CircRNA-Foxo3, a downregulated circRNA in NSCLC, acts as a tumor-suppressor to negatively target oncogenic miR-155 [28]. CircRNAs such as circ_0001649 [27] and circPTPRA [29], are expressed at a relatively low level in NSCLC to produce anti-proliferative, anti-tumorigenic, and pro-apoptotic effects on NSCLC cells. Notably, the functional roles of circRNAs are quite diversified in different cancers. CircRNA-Foxo3, for example, has been shown to be expressed at different levels and exert discrepant roles in five different cancers (breast [30], esophageal squamous cell [31], prostate [32], bladder [33], and urothelial carcinoma [34]). The underlying mechanisms of their aberrant expression and functions are unclear at present. Previously, Tan et al. reported that a tumor-promoting circRNA (F-circEA-4a) was generated from an oncogenic fusion gene (EML4-ALK) in NSCLC [35], and the altered expression of this circRNA may arise from chromosomal translocations. Other potential mechanisms, such as alterations in *cis*-elements, transcription, and spliceosomal machinery have also been suggested for the deregulation of circR-NAs [36]. It remains to be explored how circ_0017109 is upregulated in NSCLC cells.

To acts as the molecular sponge of miRNAs is the most frequently described role of circRNAs. This function was first identified in a seminal study by Hansen and colleagues, in which ciRS-7 adsorbs miR-7 and results in increased expression of miR-7 targets. In NSCLC, many of aberrantly expressed circRNAs have been shown to act as a miRNA sponge. For instance, the oncogenic circRNA_100,146 contains binding sites for miR-361-3p and miR-615-5p [26], whereas tumor suppressor circ_0001649 can absorb miR-331-3p and miR-338-5p [27]. Similarly, in our study, we showed

that circ 0017109 serves as miR-671-5p sponge to negative regulate its activity. We further demonstrated circ 0017109/miR-671-5p regulates the expression of FZD4, thereby modulating the activity of Wnt/βcatenin signaling. CircRNA may also regulate epithelial-mesenchymal transition (EMT) in cancer cells. For instance, circPTK2 can inhibit the oncogenic activity of miR-429 and miR-200b-3p to suppress EMT and tumor metastasis [37]. Wnt signaling pathway is frequently deregulated in cancers, and contributes to EMT [38]. In NSCLC study, previous studies showed that the downregulation of miR-3127-5p regulates Wnt/ FZD4/β-catenin signaling axis and promotes mesenchymal transformation [39], and it was reported that high FZD4 expression level is related to the poor prognosis of NSCLC [40]. Whether circ_0001649 also modulates EMT process and cell invasion in NSCLC cells warrants further investigation.

To conclude, we reported the overexpression of circ_0017109 in NSCLC and its upregulation may contribute to the development of NSCLC by promoting cell proliferation and inhibiting apoptosis. In NSCLC cells, circ_0017109 acts as the molecular sponge to downregulate miR-671-5p while activating FZD4/Wnt/ β -catenin signaling. Collectively, these results uncover a novel role of miR-671-5p in the progression of NSCLC, indicating that circ_0017109 may be employed as the diagnostic and prognostic biomarker for NSCLC patients.

Material and methods

Human NSCLC tissues

A total number of 50 NSCLC tumor samples and matched non-carcinoma lung samples were collected at the Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). This study was approved by the medical research ethics committee of Tianjin Medical University Cancer Institute and Hospital. All the patients signed the informed consent before surgery. The NSCLC tumor samples and adjacent normal samples were collected and snap-frozen in liquid nitrogen freezing before the preservation under $-80\,^{\circ}\mathrm{C}.$

Cell culture and transfection

Human bronchial epithelial cells (HBE) and human NSCLC cells (CALU3, CALU6, A549, H1229), and human renal epithelial cell line (H293T) were acquired from American Type Culture Collection (Virginia, USA). Cells were cultured win DMEM that contained 10% FBS (Gibco, NY, USA) and 100 U/ml of penicillin and 100 μ g/ml of streptomycin (Sigma, Germany) in a humid incubator under 5% CO₂ at 37 °C. pcDNA3.1-FZD4 expression plasmid, small interfering RNA (siRNA) of circ_0017109, control siRNA, miR-671-5p

inhibitor, miR-671-5p mimics and the corresponding negative controls (NCs) were provided by Genomeditech Co., Ltd. (Shanghai, China). Transfections were performed with Lipofectamine 2000 (Invitrogen) in line with specific instructions. Briefly, in 6-well plates, 60% confluent cells were transfected with 6 μ g of pcDNA3.1-FZD4, or 50 nM of miRNA mimic, inhibitor or siRNA according to manufacturer's instruction. After transfection for 48-h, the cells were collected for further experimental analysis.

Quantitative real-time PCR (qRT-PCR)

TRIzol reagent (Invitrogen, USA) was employed for RNA extraction. 1 µg of RNA sample was prepared into cDNA using PrimeScript II 1st Strand cDNA Synthesis Kit (TaKaRa, Tokyo, Japan) in line with specific protocols. CFX96 Touch Real-time PCR detection system (Bio-Rad, Hercules) was adopted for qPCR analysis using specific primers and SYBR Premix Ex Tag II (Takara). GAPDH or U6 was used as controls for protein-coding gene or non-coding RNA respectively, and the results were analyzed using the $2^{-\Delta\Delta CT}$ method. For miR-671-5p, reverse transcription was performed using Taqman MiRNA Reverse Transcription Kit (Applied Biosystems, MIMAT00038800). The primer sequences used in the study were as follows: circ_0017109, 5'-AGATTCCGT TCGGCTCCTCC-3' (F) and GCACTGGTGTCTGTTG TTAGC-3' (R); FZD4, 5'-CCTCGGCTACAACGTGAC C-3' (F) and 5'-TGCACATT GGCACATAAACAGA-3' (R); U6, 5'-GACAGTCAGCCGCATCTTCT-3' (F) and 5'-GCGCCCAATACGACCAAATC-3' (R); GAPDH; 5'-CTCGCTTCGGCAGCACA-3' (F) and 5'-AACGCT TCACGAATTTGCGT-3'(R).

Treatment with RNase R

A total amount of $5 \mu g$ RNA was equally divided into two portions: one was treated with 3 units of RNase R (Epicenter, Madison, WI) under $37 \,^{\circ}$ C for $15 \, \text{min}$, and the other was incubated at the same condition without RNase R (Mock). After treatment, RNA samples were collected by RNeasy MinElute Cleaning Kit (Qiagen, Germany), which was further analyzed via qRT-PCR.

Subcellular fractioning

Nuclear and Cytoplasmic RNA Purification Kit (Norgenbiotek Corporation, Thorold, Canada) was adopted for the nuclear and cytoplasmic fractioning, and the subsequent RNA isolation from A549 and H1299 cells. Circ_0017109 expression levels in different fractions were evaluated through qRT-PCR, with U6 and GAPDH being nuclear and cytoplasmic references, respectively.

Colony formation and CCK-8 proliferation assay

For colony formation experiment, cells (1000/well) were seeded into the 6-cm culture dish, and cultured for 2 weeks with medium replenishment every 2 days. On day 14, cells were subjected to 4% paraformaldehyde (PFA) fixation and the staining of 0.4% crystal violet (Sigma, Germany) for 20 min. Colonies that contained over 10 cells were counted under light mode of an FV1000 microscope (Olympus, Tokyo, Japan), at 200X magnification.

CCK-8 kit (Abcam, ab228554) was utilized to detect cell proliferation following specific instructions. 48 h post transfection, 2000 cells were seeded into each well in 96-well plates and the cells were cultured for different durations. At indicated time point, the cells were mixed with CCK-8 reagent (20 $\mu L/\text{well}$), followed by 2-h incubation under 37 °C. The absorbance (OD) measurement was conducted using a microplate reader at 450 nm.

Flow cytometry analysis of apoptosis

For quantifying apoptosis level, Annexin V-FITC/Propidium Iodide kit (BCT- Adipogen, XAP2102-TT01) was used to stain cells following the manufacturer's instructions. Briefly, 1×10^6 cells in 1 ml Annexin V staining buffer was mixed with 1 μl Annexin V dye and 1 μl Propidium Iodide reagent. After 15-min staining, the cells were washed twice with staining buffer and then analyzed using BD FACSCalibur Flow Cytometer (BD Biosciences).

Western blotting (WB) assay

Protein samples collection was performed using RIPA buffer (KeyGen, Shanghia, China) on ice for 15 min. Total protein contents were quantified by an Enhanced BCA Protein Assay Kit (Beyotime, Beijing, China). Aliquots of protein were loaded onto 10% SDS-PAGE gel, followed by transfer onto PVDF membranes (Millipore, Darmstadt, Germany). The membranes were subjected to blocking using 5% bovine serum albumin (BSA) for 1 h. The incubation with primary antibodies was performed at 4°C overnight: cleaved caspase-3 (1:2000, Abcam, ab2302), Bcl-2 (1:2000; Abcam, ab59348), FZD4 (1:1500; Bioss, bs-13217R), β-catenin (1:1500; Bioss, bs-1165R), non-phospho (Active) β-catenin (1:1000; Cell Signaling Technologies, 8814), cyclin D1 (1:2000; Abcam, ab134175), c-Myc (1:1500; Abcam, ab190026), or GAPDH (1:5000; Bioss, bs-2188R). The next day, the membranes were washed 4 times with TBST buffer and then further labeled with HRP-linked secondary antibody (1:10000; Invitrogen, 61-6520) for 1h at room temperature. After rinsing for 4 times signal development was conducted using a chemiluminescence kit (Santa Cruz, TX, USA), and the protein bands were photographed under a gel imager (Biorad, CA, USA).

Luciferase reporter assay

H293T cells were used for dual luciferase reporter assay. In 96-well plates, cells were transfected with dual luciferase reporter with wild type (WT binding site or the reporter with mutated binding sequences (MUT), in the presence of miR-671-5p mimics or miR-NC. After 48h, Luciferase Reporter Assays Substrate Kit (Abcam, ab228546) was adopted for measuring the relative luciferase activities of Firefly and Renilla luciferase in line with specific protocols.

RNA pull-down assay

Cells were transfected with 50 nM of biotinylated negative control (bio-NC) or miR-671-5p mimics (bio-miR-671-5p) using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, USA). 48h post transfection. Cell lysate was collected using IP lysis buffer (Beyotime, Beijing, China), with 10% lysate being saved as the input sample. The remaining sample was mixed with 50 µl C-1 streptavidin magnetic beads (Invitrogen, USA) under 4°C for 2h. The beads were then washed 4 times with IP lysis buffer, followed by RNA sample purification with RNeasy Mini Kit (Qiagen, Germany). The relative level of circ_0017109 in each sample was determined by qRT-PCR.

RNA immunoprecipitation

Cells were lysed using an Imprint® RNA Immunoprecipitation Kit in line with specific instructions (Sigma, Germany). One milliliter of cell lysate (1 million cells) was mixed with 5 µg anti-Ago2 or 5 µg IgG isotype, which was immobilized on protein-A magnetic beads. The mixture was incubated at 4°C overnight. The beads were rinsed 3 times using the immunoprecipitation buffer, and the RNA samples associated with the beads were extracted using TRIzol reagent (Invitrogen, USA). qRT-PCR was employed for measuring the immunoprecipitated RNAs.

Mouse xenograft assay

A549 cells with stable sh-circ_0017109 expression were generated by lentiviral transduction. pLKO.1-Puro lentiviral vector with circ_0017109 shRNA or scramble control shRNA (sh-NC) was provided by Genomeditech Co., Ltd. (Shanghai, China). The production of lentivirus was conducted in 293 T cells by GenePharma Co. Ltd. (Shanghai, China). Cells infected with lentivirus were selected with 800 ng/mL puromycin for 2 weeks before inoculation. Adult BALB/c nude mice (~25–30 g) were provided by National Resource Center for Mutant Mice of China

(Nanjing, China). Nude mice were raised in a controlled environment at $22\,^{\circ}\mathrm{C}$ with $12\mathrm{h}$ light/dark cycle. The animals were assigned to two groups (n=6 each). To establish mouse xenograft model of NSCLC, each mouse was injected with 2×10^6 A549 cells (stable expression of circ_0017109 shRNA or sh-NC) in PBS ($150\,\mu\mathrm{L}$) subcutaneously via flanks. Tumor size was measured every week using a caliber. After 4weeks, euthanasia of mice was performed using 20% of carbon dioxide in a closed chamber for $15\,\mathrm{min}$ until no movement was observed. Tumor was then dissected for subsequent analysis. All the animal experimental protocols were conducted in compliance with animal use and care guidelines of Tianjin Medical University Cancer Institute and Hospital, and were approved by the corresponding animal experimental committee.

Statistical analysis

SPSS19.0 and Prism (GraphPad Sofeware 7.0) were adopted for statistical analysis. Data were displayed as mean \pm SD. Student's t-test (two-tailed) was adopted for two group comparison, and one-way or two-way ANOVA was utilized for multiple comparisons. Pearson's correlation coefficient was utilized to analyze associations of gene expressions. Kaplan Meier curve was plotted for assessing the overall survival of NSCLC patients, while results were examined using log-rank t-test. The different was considered as significant if p < 0.05.

Abbreviations

BC: Breast cancer; CCK-8: Cell counting kit-8; circRNA: Circular ribonucleic acid; CRC: Colorectal cancer; FCM: Flow cytometry; FZD4: Frizzled-4; GBM: Glioblastoma; GC: Gastric cancer; K-M: Kaplan-Meier; LC: Lung cancer; LNM: Lymph node metastasis; NSCLC: Non–small cell lung cancer; qRT-PCR: Quantitative real-time PCR; WB: Western blotting.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12890-022-02209-2.

Additional file 1: Fig. S1. Circ_0017109 promotes cell growth and inhibits apoptosis of NSCLC cells. (A) Circ_0017109 expression within H1299 and A549 cells after the transfection of si-circ_0017109#2 or si-NC. (B) CCK-8 assay in H1299 and A549 cells after the transfection of si-circ_0017109#2 or si-NC. (C) Apoptosis detection in H1299 and A549 cells after the transfection of si-circ_0017109 or si-NC. ***, P < 0.01, and ****, P < 0.001.

Additional file 2: Fig. S2. Validation of the expression of miRNA targets between NSCLC cells and HBE cells. (A) CircInteractome database (https://circinteractome.nia.nih.gov/) revealed multiple potential miRNA targets of circ_0017109. (B) qRT-PCR analysis of miRNA expression between NSCLC cells and HBE cells. All data were normalized to the expression level in HBE cells. ****, P < 0.001.

Additional file 3: Fig. S3. qRT-PCR analysis of FZD2, FZD3, FZD4 and FZD7 in NSCLC cells and HBE cells. All data were normalized to the expression level in HBE cells. *, P<0.05, ***, P<0.01****, P<0.001.

Additional file 4.

Acknowledgements

None.

Authors' contributions

Bo Yang: manuscript drafting and revision, and study concept and design. Bin Zhang: manuscript drafting and revision, study concept and design, collection, assembly, interpretation of the data, and figure drawing. Bo Yang, Bin Zhang, Qi Qi, and Changli Wang: manuscript writing and final approval of the manuscript.

Funding

Not applicable.

Availability of data and materials

The data-sets generated in this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital Hospital, and all the procedures were carried out in accordance with the approved guidelines. All the patients provided informed consent before the experiments.

The animal experimental protocols were approved by the animal use and care Committee of Tianjin Medical University Cancer Institute and Hospital and conducted in strict accordance to the Standards of Laboratory Animal Experimental Guidelines published by the Ministry of Science and Technology of the People's Republic of China in 2006.

Our manuscript reporting adheres to the ARRIVE guidelines.

Consent for publication

Not applicable.

Competing interests

All authors report no conflicts of interest.

Author details

¹Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-hu-xi Road, Ti-Yuan-Bei, He XI Disrict, Tianjin 30060, P.R. China. ²National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-hu-xi Road, Ti-Yuan-Bei, He XI Disrict, Tianjin 30060, P.R. China. ³Tianjin's Clinical Research Center for Cancer, Tianjin Lung Cancer Center, Huan-hu-xi Road, Ti-Yuan-Bei, He XI Disrict, Tianjin 30060, P.R. China.

Received: 5 February 2022 Accepted: 29 October 2022 Published online: 24 November 2022

References

- Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung Cancer. Ann Glob Health. 2019;85(1):8.
- 2. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.
- Zhang HD, Jiang LH, Sun DW, et al. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25(1):1–7.
- Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–42.
- Zhang Y, Liu H, Li W, et al. CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630. Aging (Albany NY). 2017;9(6):1585–94.
- Tang W, Fu K, Sun H, et al. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Mol Cancer. 2018;17(1):137.
- Xu H, Liu Y, Cheng P, et al. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis. J Exp Clin Cancer Res. 2020;39(1):283.

- Yang H, Zhang H, Yang Y, et al. Hypoxia induced exosomal circRNA promotes metastasis of colorectal Cancer via targeting GEF-H1/RhoA axis. Theranostics. 2020;10(18):8211–26.
- Zhao Y, Hu Y, Shen Q, et al. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652. Eur Rev Med Pharmacol Sci. 2020;24(10):5281–91.
- 10. Su Y, Feng W, Shi J, et al. circRIP2 accelerates bladder cancer progression via miR-1305/Tgf- β 2/smad3 pathway. Mol Cancer. 2020;19(1):23.
- Sang Y, Chen B, Song X, et al. circRNA_0025202 regulates Tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a Axis in breast Cancer. Mol Ther. 2019;27(9):1638–52.
- 12. Xin C, Lu S, Li Y, et al. miR-671-5p inhibits tumor proliferation by blocking cell cycle in osteosarcoma. DNA Cell Biol. 2019;38(9):996–1004.
- 13. Tan X, Li Z, Ren S, et al. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. Breast Cancer Res. 2019;21(1):89.
- Tan X, Fu Y, Chen L, et al. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget. 2016;7(1):293–307.
- Li X, Diao H. Circular RNA circ_0001946 acts as a competing endogenous RNA to inhibit glioblastoma progression by modulating miR-671-5p and CDR1. J Cell Physiol. 2019;234(8):13807–19.
- Fang G, Ye BL, Hu BR, et al. CircRNA_100290 promotes colorectal cancer progression through miR-516b-induced downregulation of FZD4 expression and Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2018;504(1):184–9.
- Fan J, An X, Yang Y, et al. MiR-1292 targets FZD4 to regulate senescence and Osteogenic differentiation of stem cells in TE/SJ/Mesenchymal tissue system via the Wnt/β-catenin pathway. Aging Dis. 2018;9(6):1103–21.
- Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in Cancer. Cell. 2019;176(4):869–81.e13.
- Glažar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. RNA. 2014;20(11):1666–70.
- Qin S, Zhao Y, Lim G, et al. Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression. Biomed Pharmacother. 2019;111:244–50.
- Tian X, Zhang L, Jiao Y, et al. CircABCB10 promotes nonsmall cell lung cancer cell proliferation and migration by regulating the miR-1252/ FOXR2 axis. J Cell Biochem. 2019;120(3):3765–72.
- Li Y, Hu J, Li L, et al. Upregulated circular RNA circ_0016760 indicates unfavorable prognosis in NSCLC and promotes cell progression through miR-1287/GAGE1 axis. Biochem Biophys Res Commun. 2018;503(3):2089–94.
- Zong L, Sun Q, Zhang H, et al. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacother. 2018;102:639–44.
- Su C, Han Y, Zhang H, et al. CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-κB signalling. J Cell Mol Med. 2018;22(6):3097–107.
- Zhang PF, Pei X, Li KS, et al. Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019;18(1):179.
- Chen L, Nan A, Zhang N, et al. Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol Cancer. 2019;18(1):13.
- 27. Liu T, Song Z, Gai Y. Circular RNA circ_0001649 acts as a prognostic biomarker and inhibits NSCLC progression via sponging miR-331-3p and miR-338-5p. Biochem Biophys Res Commun. 2018;503(3):1503–9.
- 28. Zhang Y, Zhao H, Zhang L. Identification of the tumor-suppressive function of circular RNA FOXO3 in non-small cell lung cancer through sponging miR-155. Mol Med Rep. 2018;17(6):7692–700.
- Wei S, Zheng Y, Jiang Y, et al. The circRNA circPTPRA suppresses epithelialmesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p. EBioMedicine. 2019;44:182–93.
- Lu WY. Roles of the circular RNA circ-Foxo3 in breast cancer progression. Cell Cycle. 2017;16(7):589–90.
- Xing Y, Zha WJ, Li XM, et al. Circular RNA circ-Foxo3 inhibits esophageal squamous cell cancer progression via the miR-23a/PTEN axis. J Cell Biochem. 2020;121(3):2595–605.
- Shen Z, Zhou L, Zhang C, et al. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett. 2020;468:88–101.

- Li Y, Qiao L, Zang Y, et al. Circular RNA FOXO3 suppresses bladder Cancer progression and metastasis by regulating MiR-9-5p/TGFBR2. Cancer Manag Res. 2020;12:5049–56.
- 34. Wang C, Tao W, Ni S, et al. Circular RNA. Onco Targets Ther. 2019;12:8085–94.
- Tan S, Sun D, Pu W, et al. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer. Mol Cancer. 2018;17(1):138.
- Wu Q, Li P, Wu M, et al. Deregulation of circular RNAs in Cancer from the perspectives of aberrant biogenesis, transport and removal. Front Genet. 2019:10:16.
- Wang L, Tong X, Zhou Z, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer. Mol Cancer. 2018:17(1):140.
- 38. Li HJ, Ke FY, Lin CC, et al. ENO1 promotes lung Cancer metastasis via HGFR and WNT signaling-driven epithelial-to-Mesenchymal transition. Cancer Res. 2021;81(15):4094–109.
- 39. Yang Y, Sun Y, Wu Y, et al. Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/ β -catenin signaling in non-small-cell lung cancer. Mol Carcinog. 2018;57(7):842–53.
- Lin J, Zandi R, Shao R, Pertsemlidis A, Wistuba II, Wu X, Roth JA, Ji L, et al. A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. Sci Rep. 2017;7(1):9029.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

